ONC-PluReceptor NK cells
PreclinicalCell therapy
ONC-PluReceptor NK cells is one of 8 small molecule programs targeting Recurrent B-Cell Non-Hodgkin Lymphoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Recurrent B-Cell Non-Hodgkin Lymphoma
#DrugCompanyPhaseTrials
1Epkinly
GenmabPhase 2
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Rituxan
RochePhase 1
Velcade
SShilpa Grover, MD, MPH
Phase 1
Alisertib
TakedaPhase 1
Fludara
SanofiPreclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
ONC-PluReceptor NK cells
MM.D. Anderson Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ONC-PluReceptor NK cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Preclinical[1]
- Company
- MM.D. Anderson Cancer Center